The position points provided to the pCPA here represent a compilation of initial positions and themes expressed by member patient organizations, and the BMC looks forward to further consideration and consultation. [...] • As the pTAP process is developed, the pCPA must make every effort to ensure that the framework is constructed in a way that ensures that drug developers are encouraged and willing to participate so that opportunities for gains in timely access to necessary medication for patients are realized. [...] Unnecessary rigidity and inability to accommodate exceptional situations will risk and not contribute to the success of the initiative. [...] The BMC seeks timely access to a comprehensive range of medically necessary, safe, and effective drugs and related treatments, informed by patient-driven evidence and values, and delivered equitably and affordably to all patients in Canada. [...] In 2012, the BMC was registered under the federal Not-for-profit Corporations Act and operates under the direction of a Board of Directors comprised of representatives of member organizations and elected annually.
- Pages
- 3
- Published in
- Canada
